Literature DB >> 18456323

Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.

Clara Cesana1, Catherine Klersy, Bruno Brando, Annamaria Nosari, Barbara Scarpati, Linda Scampini, Alfredo Molteni, Guido Nador, Luca Santoleri, Marta Formenti, Marina Valentini, Antonino Mazzone, Enrica Morra, Roberto Cairoli.   

Abstract

We studied circulating (C)CD34(+) cells by flow cytometry in 96 patients with myelodysplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34(+) counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/microl were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/microl more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/microl cut-off of circulating CD34(+) cells retains prognostic utility, especially in intermediate-risk MDS.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18456323     DOI： 10.1016/j.leukres.2008.03.028

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  5 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia.

Authors:  Cuiling Zhang; Haibo Dong; Yipeng Lin; Peipei Xu; Rongfu Zhou; Hui Zeng
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-17       Impact factor: 0.900

3.  Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias.

Authors:  Hooman H Rashidi; Xiangdong Xu; Huan-You Wang; Nelofar Q Shafi; Karuna Rameshkumar; Karen Messer; Brian R Smith; Michal G Rose
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

4.  Significance of telomere capture in myelodysplastic syndromes.

Authors:  Hany A Labib; Sheren Elshorbagy; Neveen G Elantonuy
Journal:  Med Oncol       Date:  2014-09-07       Impact factor: 3.064

5.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors:  Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.